Evidence map›Paper›PMID 36925919›Full record

ArticleFrontiers in oncology2023

Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?

Francesca Negri, Lorena Bottarelli, Giuseppe Pedrazzi, Michele Maddalo, Ludovica Leo, Gianluca Milanese, Roberto Sala, Michele Lecchini, Nicoletta Campanini, Cecilia Bozzetti and 8 more

Open access · goldFull text read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. The Impact of Cancer Stem Cells in Colorectal Cancer.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Francesca NegriGastroenterology and Endoscopy Unit, University Hospital of Parma, Parma, Italy.
Lorena BottarelliPathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Giuseppe PedrazziDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Michele MaddaloMedical Physics Department, University Hospital of Parma, Parma, Italy.
Ludovica LeoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Gianluca MilaneseRadiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Roberto SalaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Michele LecchiniRadiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Nicoletta CampaniniPathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Cecilia BozzettiOncology Unit, University Hospital of Parma, Parma, Italy.
Andrea ZavaniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Gianluca Di RienzoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Cinzia AzzoniPathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Enrico Maria SiliniPathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Nicola SverzellatiRadiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Federica GaianiGastroenterology and Endoscopy Unit, University Hospital of Parma, Parma, Italy.
Gian Luigi De' AngelisGastroenterology and Endoscopy Unit, University Hospital of Parma, Parma, Italy.
Letizia GnettiPathology Unit, University Hospital of Parma, Parma, Italy.
University of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Notch intracellular domain (NICD) and its ligands Jagged-1(Jag1), Delta-like ligand (DLL-3) and DLL4 play an important role in neoangiogenesis. Previous studies suggest a correlation between the tissue levels of NICD and response to therapy with bevacizumab in colorectal cancer (CRC). Another marker that may predict outcome in CRC is radiomics of liver metastases. The aim of this study was to investigate the expression of NICD and its ligands and the role of radiomics in the selection of treatment-naive metastatic CRC patients receiving bevacizumab. Methods: Immunohistochemistry (IHC) for NICD, Jag1 and E-cadherin was performed on the tissue microarrays (TMAs) of 111 patients with metastatic CRC treated with bevacizumab and chemotherapy. Both the intensity and the percentage of stained cells were evaluated. The absolute number of CD4+ and CD8+ lymphocytes was counted in three different high-power fields and the mean values obtained were used to determine the CD4/CD8 ratio. The positivity of tumor cells to DLL3 and DLL4 was studied. The microvascular density (MVD) was assessed in fifteen cases by counting the microvessels at 20x magnification and expressed as MVD score. Abdominal CT scans were retrieved and imported into a dedicated workstation for radiomic analysis. Manually drawn regions of interest (ROI) allowed the extraction of radiomic features (RFs) from the tumor. Results: A positive association was found between NICD and Jag1 expression (p < 0.001). Median PFS was significantly shorter in patients whose tumors expressed high NICD and Jag1 (6.43 months vs 11.53 months for negative cases; p = 0.001). Those with an MVD score ≥5 (CD31-high, NICD/Jag1 positive) experienced significantly poorer survival. The radiomic model developed to predict short and long-term survival and PFS yielded a ROC-AUC of 0.709; when integrated with clinical and histopathological data, the integrated model improved the predictive score (ROC-AUC of 0.823). Discussion: These results show that high NICD and Jag1 expression are associated with progressive disease and early disease progression to anti VEGF-based therapy; the preliminary radiomic analyses show that the integration of quantitative information with clinical and histological data display the highest performance in predicting the outcome of CRC patients.

Indexed as

bevacizumabcolorectal cancerJagged-1Notch signaling pathwaytherapy resistance

Identifiers

PMID36925919
PMCPMC10011088
OpenAlexW4323320041

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read23
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.